NCT07226063
Clinical Trial Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, Variants, or PubMed publications.

Have questions, comments, or suggestions? - Let us know!

Email us at : ckbsupport@genomenon.com

NCT ID NCT07226063
Title Maintenance Zanzalintinib and Durvalumab in Participants With Advanced Hepatocellular Cancer
Recruitment Not yet recruiting
Gender both
Phase Phase II
Variant Requirements No
Sponsors Amit Mahipal
Indications
Therapies
Age Groups: adult | senior
Covered Countries USA


No variant requirements are available.